


北醫圖書館APP服務 下載登入使用指引

北醫六十 邁向榮耀
TMU60
1960~2020



APP-實證資源類

uCentral

下載行動版



行動下載

Home Favorites Notes Prime **Mobile** Browse

Welcome, Judy Lee



Sign out



Search uCentral



Home Favorites Notes Prime **Mobile** Sign out



Welcome to uCentral

Have you downloaded uCentral Mobile page for more information

Search uCentral

Johns Hopkins ABX Guide




Prime For You

Updated



Prime Journals



Get uCentral on your Mobile Device

uCentral is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research.




Download

手機、平板皆可安裝

安裝完成可離線使用

✓ To Install or Reinstall your Application

Select your platform to view detailed installation instructions.



1. Open the App Store on your mobile device.
2. Search **uCentral** from Unbound Medicine
3. Download **uCentral**
4. Select Sign In, then enter your username and password.

Your subscription to uCentral includes access to the web application while your subscription is active to find up-to-date answers to clinical questions:

<https://www.unboundmedicine.com/ucentral>

✓ To Install or Reinstall your Application

Select your platform to view detailed installation instructions.






Install the Application on your Android Device




Click the button below to open the **uCentral** page in Google play.







手機安裝





下載App至手機畫面




查詢本校教職員研究成果






查詢本校圖書館最新公告/推播服務





查詢PubMed及瀏覽期刊/文獻新知



工具書資料查詢



內文中查詢



全文連結

Johns Hopkins ABX Guide
Tigecycline

INDICATIONS

FDA

- Complicated skin and skin structure infections (including those caused by [MRSA](#) and [vancomycin](#)-susceptible *E. faecalis*).
 - Author's comment: avoid in severe infections +/- bacteremia.
- Complicated intra-abdominal infections (as a single agent).
 - Author's comment: avoid in severe infection +/- bacteremia.
- [Community-acquired bacterial pneumonia](#) caused by *S. pneumoniae* (PCN-susceptible isolates), *H. influenzae* (beta-lactamase negative isolates), and *Legionella pneumophila*.
 - Author's comment: not a first-line agent and generally not used for [CAP](#).

NON-FDA APPROVED USES

- HAP/VAP due to MDR GNR but high rates of clinical failure reported [\[3\]](#).
 - In critically ill patients, consider using tigecycline in combination with carbapenem or [colistin](#).

FORMS

Johns Hopkins ABX Guide
Tigecycline

- Chemaly RF et al: Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. *Medicine (Baltimore)* 88:211, 2009 [\[PMID:19593226\]](#)
- Bergallo C et al: Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. *Diagn Microbiol Infect Dis* 63:52, 2009 [\[PMID:18990531\]](#)

Comment: This is a Wyeth sponsored random double-blind phase 3 trial involving 418 pts w CAP. Pts were randomized to receive either tigecycline or levofloxacin (IV for at least 6 days) x 7-14 days. Tigecycline was comparable to levofloxacin with 90.6% vs. 87.2% response rate in the tigecycline and levofloxacin treated group, respectively. Nausea and vomiting were more common in the tigecycline treated group. Patients in this study received over 6 days of IV antibiotics for an indication that can be treated with oral antibiotics. Tigecycline is generally not recommended for the treatment of CAP, but can be considered as a second line treatment of MDR Acinetobacter (in combination) and Stenotrophomonas

- Anthony KB et al: Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. *Clin Infect Dis* 46:567, 2008 [\[PMID:18300030\]](#)

Citation

Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.

FREE Publisher Full Text

[TMU Fulltext](#)

Related Articles

Grapherence [↓ 12]

Abstract

Tigecycline, the first in a new class of glycylicyclines, has been approved for the treatment of complicated skin and skin structure and intraabdominal infections in adults. However, clinical data on its safety and effectiveness in cancer patients are lacking. We reviewed the records of all

相關文獻&文獻引用關係

Results

Articles related to "Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution." (1,541)

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including *Enterobacter* species, *Acinetobacter baumannii* and *Klebsiella pneumoniae*.

J Antimicrob Chemother 2008; 62 Suppl 1:i29-40

Vasilev K, Reshedko G, ... 309 Study Group

CONCLUSIONS: In this non-comparative study, tigecycline appeared safe and efficacious in patients with difficult-to-treat serious infections caused by resistant Gram-negative organisms.

Tigecycline for the treatment of *Acinetobacter* infections: a case series.

Ann Pharmacother 2008; 42(9):1188-94

Gallagher JC, Rouse HM

CONCLUSIONS: In this case series, most patients did not have clinically or microbiologically favorable outcomes with tigecycline therapy. No patient had isolate that was fully susceptible to tigecycline. Data from more studies are needed before tigecycline ca...

Citation

Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.

FREE Publisher Full Text


TMU Fulltext

Related Articles

Grapherence [↓ 12]

Abstract

Tigecycline, the first in a new class of glycylicyclines, has been approved for the treatment of complicated skin and skin structure and intraabdominal infections in adults. However, clinical data on its safety and effectiveness in cancer patients are lacking. We reviewed the records of all



標示重點或筆記

Johns Hopkins ABX Guide
Vancomycin

INDICATIONS

FDA

- Bone and joint infections
- Pneumonia
- **COPY** **NOTE** **FULLTEXT SEARCH** in PCN
- Oral vancomycin: antibiotic-associated pseudomembranous colitis caused by *C. difficile* and enterocolitis caused by *S. aureus* (including MRSA)

NON-FDA APPROVED USES

- Hardware-associated infections

FORMS

brand name	preparation	manufacturer	route	form
Vancocin, Lyphocin	Vancomycin HCl	Generic manufacturers (Eli Lilly, Fujisawa, Schein and others)	IV	vial
Vancocin Pulvule	Vancomycin HCl	Viropharma	oral	pulvul

特別注意

Hardware-associated infections

FORMS

brand name	preparation	manufacturer	route	form
Vancocin, Lyphocin	Vancomycin HCl	Generic manufacturers (Eli Lilly, Fujisawa, Schein and others)	IV	vial
Vancocin Pulvule	Vancomycin HCl	Viropharma	oral	pulvul

Johns Hopkins ABX Guide
Vancomycin

FDA

- Bone and joint infections
- Pneumonia
- Septicemia
- Endocarditis treatment and prophylaxis (in PCN allergic pts)
- Oral vancomycin: antibiotic-associated pseudomembranous colitis caused by *C. difficile* and enterocolitis caused by *S. aureus* (including MRSA)

NON-FDA APPROVED USES

- Hardware-associated infections

FORMS

brand name	preparation	manufacturer	route	form
Vancocin, Lyphocin	Vancomycin HCl	Generic manufacturers (Eli Lilly, Fujisawa, Schein and others)	IV	vial
Vancocin Pulvule	Vancomycin HCl	Viropharma	oral	pulvul

uCentral

★ Favorites 📄 Notes ⌚ Recent

FILTER ▼

Vancomycin

Generic manufacturers (Eli Lilly, Fujisawa, Schein 小心)

Vancomycin

Oral vancomycin: antibiotic-associated pseudomembranous colitis caused by *C. difficile* and enterocolitis caused by *S. aureus* (including MRSA) 特別注意



Thank You!